Skip to main content

Table 1 Baseline clinical characteristics of study population

From: Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

Parameter E+L group M+I group p-value
Age (years) 59.9 ± 9.8 60.7 ± 8.9 0.648
Diabetes duration (years) 7.2 ± 5.6 9.0 ± 5.3 0.092
RAS-blockade (−) 26 (51.0%) 27 (58.7%) 0.297
Weight (kg) 90.2 ± 14 93.1 ± 17 0.348
BMI (kg/m2) 30.4 ± 3.6 31.3 ± 3.9 0.222
Fasting plasma glucose (mg/dl) 156.2 ± 29 164.7 ± 34 0.240
HbA1c (%/mmol/mol) 7.69 ± 0.7/61 ± 7.7 7.73 ± 0.8/61 ± 8.7 0.780
Office systolic BP (mmHg) 132 ± 13 131 ± 13 0.774
Office diastolic BP (mmHg) 80 ± 8 78 ± 9 0.489
Office heart rate (beats/min) 71.3 ± 10 72.2 ± 10 0.671
  1. Data are means ± SD or n (%)
  2. RAS: renin-angiotensin system; BP: blood pressure